Number of development milestone payments the Company received

No definition available.

Name:	regn_NumberofdevelopmentmilestonepaymentstheCompanyreceived
Namespace Prefix:	regn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of development cost for the territory outside the United States previously required to be paid for under the collaboration.

+ References

No definition available.

+ Details

Name:	regn_PercentageofdevelopmentcostfortheterritoryoutsidetheUnitedStatespreviouslyrequiredtobepaidforunderthecollaboration
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of development milestone payments Bayer HealthCare is obligated to reimburse the Company for payments that the Company makes to Sanofi related to the Company's acquisition of rights to antibodies targeting the PDGF family of receptors.

+ References

No definition available.

+ Details

Name:	regn_Percentageofdevelopmentmilestonepaymentstobereimbursed
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of global development cost to be paid by the collaboration partner under the collaboration

+ References

No definition available.

+ Details

Name:	regn_Percentageofglobaldevelopmentcosttobepaidbythecollaborationpartnerunderthecollaboration
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_PDGFMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_PDGFRbetaoutsidetheUSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements (PDGFR-beta Antibody) (Details) $ in Millions	3 Months Ended		6 Months Ended	9 Months Ended	13 Months Ended
	Jun. 30, 2015 USD ($)	Mar. 31, 2014 USD ($)	Jun. 30, 2014	Sep. 30, 2015	Jan. 31, 2015 USD ($)
Collaboration Agreement [Line Items]
Number of development milestone payments the Company received			3,000,000
PDGF
Collaboration Agreement [Line Items]
Percentage of global development cost to be paid by the collaboration partner under the collaboration				25.00%
Percentage of development cost for the territory outside the United States to be paid for under the collaboration				50.00%
Percentage of development milestone payments to be reimbursed				50.00%
Number of development milestone payments the Company received	1	2
Deferred Revenue, Additions		$ 2.5			$ 25.5
Revenue Recognition, Milestone Method, Revenue Recognized	$ 5.0
PDGFR-beta outside the US [Member]
Collaboration Agreement [Line Items]
Proceeds from Collaborators		$ 25.5